Neuraxis Inc (NRXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -7,801 | -8,242 | -14,627 | -4,780 |
| Depreciation Amortization | 60 | 164 | 4,922 | 136 |
| Accounts receivable | 47 | -179 | 76 | -79 |
| Accounts payable and accrued liabilities | -458 | -607 | -388 | 1,108 |
| Other Working Capital | 610 | 141 | -666 | 1,270 |
| Other Operating Activity | 1,109 | 2,624 | 3,988 | 46 |
| Operating Cash Flow | $-6,433 | $-6,098 | $-6,694 | $-2,298 |
| Cash Flows From Investing Activities | ||||
| PPE Investments | -31 | -28 | -31 | -1 |
| Purchase Sale Intangibles | -100 | N/A | -41 | -60 |
| Other Investing Activity | -100 | 0 | -41 | -60 |
| Investing Cash Flow | $-131 | $-28 | $-72 | $-61 |
| Cash Flows From Financing Activities | ||||
| Debt Issued | N/A | 4,935 | 5,620 | 3,322 |
| Debt Repayment | -282 | -276 | -3,534 | -163 |
| Common Stock Issued | 8,827 | 26 | 5,057 | 0 |
| Other Financing Activity | -713 | 5,059 | -552 | -867 |
| Financing Cash Flow | $7,832 | $9,744 | $6,591 | $2,292 |
| Beginning Cash Position | 3,697 | 79 | 254 | 321 |
| End Cash Position | 4,965 | 3,697 | 79 | 254 |
| Net Cash Flow | $1,268 | $3,618 | $-175 | $-67 |
| Free Cash Flow | ||||
| Operating Cash Flow | -6,433 | -6,098 | -6,694 | -2,298 |
| Capital Expenditure | -31 | -28 | -31 | -1 |
| Free Cash Flow | -6,464 | -6,126 | -6,725 | -2,299 |